Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

502
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
502
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

790
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
790
Long-term Depression01:05

Long-term Depression

33.3K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
33.3K
Long-term Depression01:03

Long-term Depression

3.4K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
3.4K
Freezing Point Depression and Boiling Point Elevation03:12

Freezing Point Depression and Boiling Point Elevation

40.2K
Boiling Point Elevation
The boiling point of a liquid is the temperature at which its vapor pressure is equal to ambient atmospheric pressure. Since the vapor pressure of a solution is lowered due to the presence of nonvolatile solutes, it stands to reason that the solution’s boiling point will subsequently be increased. Vapor pressure increases with temperature, and so a solution will require a higher temperature than will pure solvent to achieve any given vapor pressure, including one...
40.2K
Depressants01:28

Depressants

437
Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
437

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Probiotic-Plant Bioactive Synergy in Gut Health: Mechanisms, Antimicrobial Activity, and Translational Challenges.

Nutrients·2026
Same author

Depression, Anxiety and Stress Among Women Treated Due to Infertility.

Journal of clinical medicine·2026
Same author

Robot-Assisted Hysterectomy for Endometrial Cancer-Own Observations.

Journal of clinical medicine·2026
Same author

Plant-Derived Spinacetin Mitigates Cyclophosphamide-Induced Hemorrhagic Cystitis in Rats.

International journal of molecular sciences·2026
Same author

Quality of Life, Menopausal Symptoms, Insomnia and Depression in Peri- and Post-Menopausal Women: A Cross-Sectional Study.

Medical science monitor : international medical journal of experimental and clinical research·2026
Same author

The Regulatory Role of FABP4 in Microbiome-Brain-Gut Communication Under High-Fat-Diet Conditions.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Feb 4, 2026

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

1.5K

Cannabinoids in depressive disorders.

Ewa Poleszak1, Sylwia Wośko1, Karolina Sławińska1

  • 1Chair and Department of Applied Pharmacy, Medical University of Lublin, Chodźki 1, PL, 20-093 Lublin, Poland.

Life Sciences
|October 6, 2018
PubMed
Summary

The endocannabinoid system, influenced by Cannabis sativa, shows potential for novel antidepressant treatments. Further research is needed to identify patient groups that may benefit from cannabinoid-based therapies.

Keywords:
CB1 receptorCB2 receptorDepressionEndocannabinoids

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.7K
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.4K

Related Experiment Videos

Last Updated: Feb 4, 2026

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

1.5K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.7K
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.4K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Cannabis sativa is a widely used plant with suggested benefits for various neurological and psychiatric conditions.
  • The endocannabinoid system's role in depression pathogenesis and treatment is under investigation.
  • Cannabinoid agents have shown potential in managing symptoms of epilepsy, multiple sclerosis, Parkinson's, and Alzheimer's diseases.

Purpose of the Study:

  • To explore the involvement of the endocannabinoid system in the treatment of depression.
  • To review the current understanding of cannabinoid agents' effects on mood disorders.
  • To identify potential therapeutic mechanisms and future research directions for depression treatment.

Main Methods:

  • Review of pre-clinical studies and published data on Cannabis sativa and the endocannabinoid system.
  • Analysis of reported pro- and antidepressant activities associated with cannabinoid consumption.
  • Examination of the neurobiological pathways potentially involved in cannabinoid-induced mood regulation.

Main Results:

  • Cannabinoid agents demonstrate both pro- and antidepressant activities.
  • Pre-clinical studies indicate that endocannabinoid receptor agonists and antagonists may function similarly to traditional antidepressants.
  • Observed effects are rapid and likely involve noradrenergic, serotoninergic, and glutamatergic neurotransmission, neuroprotection, and hypothalamic-pituitary-adrenal axis modulation.

Conclusions:

  • The endocannabinoid system offers novel therapeutic avenues for antidepressant treatment.
  • Cannabinoid-based therapies present promising options for managing depression.
  • Further clinical studies are essential to define patient populations that could benefit from these novel treatments.